C
네이처셀
007390KOSDAQ50.5 / 100
Reference Date: 2026-10-23
Financial Score18.0 / 40
News Sentiment12.5 / 25
Momentum10.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 6.8% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
NatureCell focuses on developing and selling stem cell therapies (e.g., JointStem, AstroStem), stem cell culture media, cosmetics, and beverage R&D and sales. The company is expanding its global presence through clinical trials in the U.S. and Japan, as well as a 2022 acquisition of a U.S. subsidiary. In 2024, the stem cell business accounted for approximately 68% of total revenue.
Number of Employees
83people
Average Salary
45.1M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
—Industry Average 1.203.5Point
ROE
-4.45Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
4.76Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20252.5 / 10 points
Revenue Growth Rate
2.5 / 3
Avg ▲15.6% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼302.2% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -7.4% (improving, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position3.0Point
52w lower range (35%)
Current 23,150Won52-week high 34,55052-week low 16,900
1-month return2.0Point
1m -6.84% (slight drop)
Volume trend5.0Point
Volume increasing
Detailed Disclosure
1 totalPositive 0Neutral 1Negative 0
- Neutral주요사항보고서(유형자산양수결정)2026-10-15